Luciano da Fontoura Costa

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Identifying candidates for outpatient administration of ciltacabtagene autoleucel (Cilta-cel) in relapsed-refractory multiple myeloma (RRMM)

  Blood · 2025-11-03 · 1 citations

• Talquetamab for relapsed/refractory multiple myeloma : Real-world outcomes from the US multiple myeloma immunotherapy consortium

  Blood · 2025-11-03 · 1 citations

• Association between cilta-cel dose and efficacy and toxicity outcomes for patients with Relapsed/Refractory multiple myeloma (RRMM): A real-world analysis from the US multiple myeloma immunotherapy consortium

  Blood · 2025-11-03 · 1 citations

• Long-term progression-free survival benefit with ciltacabtagene autoleucel in standard-risk relapsed / refractory multiple myeloma

  Blood · 2025-11-03 · 4 citations

• Quality-adjusted survival analysis of neurologic events with ciltacabtagene autoleucel (Cilta-cel) vs standard of care (SOC) in patients (Pts) with lenalidomide-refractory multiple myeloma (MM) who received 1–3 prior lines of therapy (LOT): Cartitude-4 trial population (Pop)

  Blood · 2025-11-03

• Predictors of early relapse following ciltacabtagene autoleucel: Informing risk-adapted therapy in relapsed/refractory multiple myeloma

  Blood · 2025-11-03

• Distinct trajectory and prognosis of measurable residual disease (MRD) in t(11;14) multiple myeloma (MM) treated with upfront quadruplet (QUAD) therapy and autologous stem cell transplantation (ASCT)

  Blood · 2025-11-03

• Safety and efficacy of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy, in relapsed/refractory multiple myeloma: Preliminary Results from the DURGA-1 Phase 1b/2 study

  Blood · 2025-11-03 · 6 citations

• Identifying high-risk profiles and adverse prognoses in relapsed/refractory multiple myeloma treated with bispecific antibodies: A real-world analysis of 943 treatment initiations

  Blood · 2025-11-03

• Assessment of pharmacodynamic efficacy biomarkers from A phase 1, first-in-human study of arlocabtagene autoleucel (arlo-cel) in relapsed and refractory multiple myeloma (RRMM)

  Blood · 2025-11-03

• Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): Identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality

  Blood · 2025-11-03 · 5 citations

• Real-world outcomes in older adults with triple-class exposed multiple myeloma

  Blood · 2025-11-03

• Definition of Transplant Ineligibility in Newly Diagnosed Multiple Myeloma: A Systematic Review

  Clinical Lymphoma Myeloma & Leukemia · 2025-09-01

• Mezigdomide (MEZI) in Novel Targeted Combinations for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from the Phase 1/2 CA057-003 Trial

  Clinical Lymphoma Myeloma & Leukemia · 2025-09-01

• A Network Meta-Analysis of Randomized Clinical Trials Comparing the Efficacy of Daratumumab Versus Isatuximab in the Treatment of Multiple Myeloma

  Clinical Lymphoma Myeloma & Leukemia · 2025-09-01

• Temporal Trends in Infectious Risk Among Multiple Myeloma Patients Treated with Daratumumab: A Meta-Analysis

  Clinical Lymphoma Myeloma & Leukemia · 2025-09-01 · 1 citations

• Mezigdomide (MEZI) in Novel Combinations Effectively Reactivates Immune System in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Including those after T-Cell–Redirecting Therapies (TCRT)

  Clinical Lymphoma Myeloma & Leukemia · 2025-09-01

• Quality-Adjusted Survival Analysis of Cilta-Cel vs Standard of Care in Lenalidomide-Refractory Multiple Myeloma Patients who Received 1–3 Prior Lines of Therapy: CARTITUDE-4 Trial Population

  Clinical Lymphoma Myeloma & Leukemia · 2025-09-01

• A Systematic Approach for Studying How Topological Measurements Respond to Complex Networks ModificationsPreprint

  ArXiv.org · 2025-05-28

• An Analytical Approach to the Jaccard Similarity IndexPreprint

  arXiv (Cornell University) · 2024-10-21 · 1 citations